活体生物治疗产品的开发:亚太微生物群联盟立场声明
亚太微生物群联盟邀请微生物组研究、微生物学、胃肠病学、内科学及生物治疗产业专家组成专家组,于2023年联盟成立会议期间通过结构化迭代圆桌讨论形成专家共识。共识声明围绕活体生物治疗产品(LBP)的开发理由、临床前研究和临床研究准备三个方面展开,强调微生物学评估、临床相关性、科学机制和安全性。
要点
- 专家组强烈推荐优先开发人源和食物来源菌株,适应症应基于临床需求和研究显示的疗效。
- 临床前评估应包括全面筛选、基因分型和表型分析,以及体外和动物研究评估功能机制与微生物学安全性。
- 临床试验(含上市后监测)须精心设计并密切监测,建立稳健的安全性和风险管理方案。
核心结论
- LBP的开发应在每个阶段都高度重视微生物学评估、临床相关性、科学机制和安全性,以确保产品的安全性、有效性和长期成功。
研究设计与样本
- 亚太微生物群联盟专家组于2023年联盟成立会议期间通过结构化迭代圆桌讨论形成专家共识。
- 专家组由微生物组研究、微生物学、胃肠病学、内科学和生物治疗产业专家组成。
主要发现
- 共识声明分为三个方面:LBP开发理由、临床前研究和临床研究准备。
- 专家组强烈推荐优先开发人源和食物来源菌株,适应症基于临床需求和研究显示的疗效。
- 临床前评估应包括全面筛选、基因分型和表型分析,以及综合体外和动物研究评估功能机制和微生物学安全性。
- 严格的细胞库管理和遗传监测对确保生产过程中产品一致性和安全性至关重要。
- 临床试验(包括上市后监测)必须精心设计并密切监测,建立稳健的安全性和风险管理方案。
关键数值与推荐
- 专家组强烈推荐优先开发人源和食物来源菌株,适应症应基于临床需求和研究显示的疗效。
- 临床前评估应包括全面筛选、基因分型和表型分析,以及综合体外和动物研究评估功能机制和微生物学安全性。
- 严格的细胞库管理和遗传监测是确保生产过程中产品一致性和安全性的必要条件。
- 临床试验(包括上市后监测)必须精心设计并密切监测,建立稳健的安全性和风险管理方案。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Live biotherapeutic products (LBPs) are biological products composed of living micro-organisms, developed to prevent, treat, or cure diseases. Examples include cultured strains of Akkermansia muciniphila and Christensenella minuta, as well as treatments using purified Firmicutes spores for recurrent Clostridioides difficile infections. There is a need for guidelines over the increasing interest in developing LBPs. A panel of microbiome experts from Asia-Pacific countries articulates their perspectives on key considerations for LBP development. DESIGN: Experts in microbiome research, microbiology, gastroenterology, internal medicine and biotherapeutics industry were invited to form a panel. During the 2023 Inauguration Conference of the Asia-Pacific Microbiota Consortium, an organised, iterative roundtable discussion was conducted to build expert consensus on critical issues surrounding the development of LBP. RESULTS: The consensus statements were organised into three main aspects: (a) rationales of LBP development, (b) preclinical studies and (c) preparation for clinical studies. The panel strongly recommended to prioritise human-derived and food-sourced strains for development, with indications based on clinical need and efficacy shown in studies. Preclinical evaluation should involve thorough screening, genotyping and phenotyping, as well as comprehensive in vitro and animal studies to assess functional mechanisms and microbiological safety. Rigorous cell banking practices and genetic monitoring are essential to ensure product consistency and safety throughout the manufacturing process. Clinical trials, including postmarketing surveillance, must be carefully designed and closely monitored, with robust safety and risk management protocols in place. CONCLUSIONS: The development of LBP should be approached with a strong emphasis on microbiological evaluation, clinical relevance, scientific mechanisms and safety at every stage. These measures are essential to ensure the safety, effectiveness and long-term success of the product.
引用
- Tseng CH, Wong S, Yu J, et al. Development of live biotherapeutic products: a position statement of Asia-Pacific Microbiota Consortium. Gut. 2025. PMID: 40011030. doi:10.1136/gutjnl-2024-334501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。